These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 1310509)

  • 1. Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines.
    Kasahara K; Fujiwara Y; Sugimoto Y; Nishio K; Tamura T; Matsuda T; Saijo N
    J Natl Cancer Inst; 1992 Jan; 84(2):113-8. PubMed ID: 1310509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines.
    Yamazaki K; Isobe H; Hanada T; Betsuyaku T; Hasegawa A; Hizawa N; Ogura S; Kawakami Y
    Cancer Chemother Pharmacol; 1997; 39(3):192-8. PubMed ID: 8996519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.
    Fukuda M; Ohe Y; Kanzawa F; Oka M; Hara K; Saijo N
    Anticancer Res; 1995; 15(2):393-8. PubMed ID: 7763011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of DNA cleavage induced by etoposide and doxorubicin in two human small-cell lung cancer lines with different sensitivities to topoisomerase II inhibitors.
    Binaschi M; Capranico G; De Isabella P; Mariani M; Supino R; Tinelli S; Zunino F
    Int J Cancer; 1990 Feb; 45(2):347-52. PubMed ID: 2154411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doxorubicin sensitivity pattern in a panel of small-cell lung-cancer cell lines: correlation to etoposide and vincristine sensitivity and inverse correlation to carmustine sensitivity.
    Jensen PB; Roed H; Sehested M; Demant EJ; Vindeløv L; Christensen IJ; Hansen HH
    Cancer Chemother Pharmacol; 1992; 31(1):46-52. PubMed ID: 1360876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topoisomerase inhibitor-induced apoptosis accompanied by down-regulation of Bcl-2 in human lung cancer cells.
    Oizumi S; Isobe H; Ogura S; Ishida T; Yamazaki K; Nishimura M; Kawakami Y; Dosaka-Akita H
    Anticancer Res; 2002; 22(6C):4029-37. PubMed ID: 12553028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression.
    Giaccone G; Gazdar AF; Beck H; Zunino F; Capranico G
    Cancer Res; 1992 Apr; 52(7):1666-74. PubMed ID: 1312895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of DNA topoisomerase II alpha expression in small cell and nonsmall cell carcinoma of the lung. In search of a mechanism of chemotherapeutic response.
    Guinee DG; Holden JA; Benfield JR; Woodward ML; Przygodzki RM; Fishback NF; Koss MN; Travis WD
    Cancer; 1996 Aug; 78(4):729-35. PubMed ID: 8756364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N; Lam YM; Pym J; Campling BG
    Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line.
    de Jong S; Zijlstra JG; de Vries EG; Mulder NH
    Cancer Res; 1990 Jan; 50(2):304-9. PubMed ID: 1967222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines.
    Jensen PB; Christensen IJ; Sehested M; Hansen HH; Vindeløv L
    Br J Cancer; 1993 Feb; 67(2):311-20. PubMed ID: 8094293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
    van Ark-Otte J; Kedde MA; van der Vijgh WJ; Dingemans AM; Jansen WJ; Pinedo HM; Boven E; Giaccone G
    Br J Cancer; 1998 Jun; 77(12):2171-6. PubMed ID: 9649129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical detection of DNA topoisomerase IIalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer.
    Kreisholt J; Sorensen M; Jensen PB; Nielsen BS; Andersen CB; Sehested M
    Br J Cancer; 1998 May; 77(9):1469-73. PubMed ID: 9652763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer.
    Shaw GL; Gazdar AF; Phelps R; Steinberg SM; Linnoila RI; Johnson BE; Oie HK; Russell EK; Ghosh BC; Pass HI; Minna JD; Mulshine JL; Ihde DC
    J Cell Biochem Suppl; 1996; 24():173-85. PubMed ID: 8806100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.
    Andoh T; Nishizawa M; Hida T; Ariyoshi Y; Takahashi T; Ueda R
    Oncol Res; 1996; 8(6):229-38. PubMed ID: 8895198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
    Zwelling LA; Slovak ML; Doroshow JH; Hinds M; Chan D; Parker E; Mayes J; Sie KL; Meltzer PS; Trent JM
    J Natl Cancer Inst; 1990 Oct; 82(19):1553-61. PubMed ID: 1976136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
    Lelièvre S; Benchokroun Y; Larsen AK
    Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells.
    Takano H; Kohno K; Ono M; Uchida Y; Kuwano M
    Cancer Res; 1991 Aug; 51(15):3951-7. PubMed ID: 1649696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of XR5944, a novel and potent topoisomerase poison.
    Stewart AJ; Mistry P; Dangerfield W; Bootle D; Baker M; Kofler B; Okiji S; Baguley BC; Denny WA; Charlton PA
    Anticancer Drugs; 2001 Apr; 12(4):359-67. PubMed ID: 11335793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential stabilization of topoisomerase-II-DNA cleavable complexes by doxorubicin and etoposide in doxorubicin-resistant rat glioblastoma cells.
    Montaudon D; Pourquier P; Denois F; de Tinguy-Moreaud E; Lagarde P; Robert J
    Eur J Biochem; 1997 Apr; 245(2):307-15. PubMed ID: 9151958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.